Calidi Biotherapeutics, Inc.
corporate_fare Company Profile
Calidi Biotherapeutics, Inc. (NYSE:CLDI) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 2 items for CLDI at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 8/10. Across its 2 most recent items scored 7 or higher, the top rating is 8/10, with 1 rated 8 or above. Recent SEC coverage for CLDI spans 10-Q, 8-K.
Recent high-impact activity:
- Calidi 10-Q Discloses Going-Concern Doubt, NYSE Equity Deficiency and Executive Pay Deferrals
- Calidi Posts $3.6M Q3 Loss, Cuts 39% of G&A, Executes $3M Restructuring to Extend Runway
Financial Snapshot
Short Interest & Short Volume
2.48 days to coverFINRA reported short interest of 135,691 shares in CLDI as of the October 30, 2026 settlement, a 17.4% decrease from the prior period — about 2.5 days to cover at its recent average daily volume. On November 20, 2026, 21.8% of CLDI volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.